Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - Novo Nordisk

Drug Profile

Liraglutide - Novo Nordisk

Alternative Names: LATIN T1D; Liraglutide; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk; University of Pennsylvania
  • Developer Cedars-Sinai Medical Center; Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Antiparkinsonians; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease; Smoking withdrawal
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2019 Novo Nordisk has application pending for six month paediatric extension to the liraglutide supplementary patent certificate in multiple European Union countries
  • 08 Aug 2019 Novo Nordisk completes a phase III trial in Obesity (In adolescents) in Belgium, Sweden, Mexico, Russia and USA (NCT02918279; EudraCT2014-004353-14)
  • 28 Jun 2019 Preregistration for Type 2 diabetes mellitus (In adolescents, In children) in European Union (SC) before June 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top